Rejuvenate Biomed

Rejuvenate Biomed is a clinical-stage biotechnology company focused on developing innovative combination small-molecule therapeutics to address age-related diseases.

Founded in October 2017 by Dr. Ann Beliën, the company is headquartered in Diepenbeek, Belgium, with additional operations in Heusden-Zolder and a corporate office in Cambridge, Massachusetts. Rejuvenate Biomed emerged from the Johnson & Johnson Innovation JLABS program and is dedicated to enhancing healthspan by targeting chronic conditions such as sarcopenia, obesity, and neurodegenerative disorders. The company utilizes advanced AI-driven platforms, including CombinAge® and CelegAge®, to identify and validate drug combinations that can restore biological systems affected by aging. Its lead candidate, RJx-01, is currently in Phase 2 clinical trials for sarcopenia and COPD-related muscle weakness. Rejuvenate Biomed is committed to partnering with pharmaceutical companies and research institutions to advance its drug development efforts, aiming to deliver effective therapies that improve the quality of life for patients facing age-related challenges.